Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus
Withdrawn before enrolling · Phase 1
Conditions studied: Systemic Lupus Erythematosus
In brief
This trial is designed to evaluate the safety of treating systemic lupus erythematosus participants with cyclophosphamide and CAMPATH-1H followed by allogeneic stem cell transplant. There will be no randomization in this study. All subjects who are determined to be eligible for the study treatment will receive cyclophosphamide and CAMPATH-1H followed by allogeneic stem cell transplant. The purpose of the intense chemotherapy is to destroy the cells in the immune system which may be causing this disease. The purpose of the stem cell infusion is to produce a normal immune system that will no longer attack body. The study purpose is to examine whether this treatment will result in improvement in the lupus disease.
Key facts
- Study ID
- NCT00278590
- Run by
- Northwestern University
- People needed
- 0
- Starts
- 2004-07-01
- Expected to finish
- 2015-07-01
- Last updated by the study team
- 2017-01-13
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University, Feinberg School of Medicine — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.